Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biofrontera ( (DE:B8FK) ) has shared an announcement.
Biofrontera AG has announced an expected impairment loss between €50 million and €65 million in its unconsolidated accounts due to reduced profit expectations for its subsidiaries, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH. This will lower the company’s consolidated net earnings for 2025 by approximately €5 million, although it will not affect the consolidated EBITDA or cash position, indicating a significant financial adjustment but maintaining operational stability.
More about Biofrontera
Biofrontera AG operates in the pharmaceutical industry, focusing on the development and commercialization of dermatological products. The company is known for its innovative treatments in skin diseases and has a market presence in various regulated and free markets across Germany.
Average Trading Volume: 3,267
Technical Sentiment Signal: Hold
Current Market Cap: €17.08M
For a thorough assessment of B8FK stock, go to TipRanks’ Stock Analysis page.